A new synthetic drug that is the equivalent of 10,000 to 15,000 pharmaceutical doses has been approved by the Food and Drug Administration.

The drug is part of a $1 billion, five-year drug development program launched by President Trump and the Department of Health and Human Services to address a shortage of synthetic drugs.

The drug, called Nexium, is designed to address the most common symptoms of Gastrodias, including nausea, diarrhea, vomiting and abdominal pain.

“The drug will provide patients with a full range of pain relief, including relief from abdominal pain, nausea and vomiting,” said Dr. Daniel G. Kahan, president of the National Gastroenterology Society.

“Nexium is also designed to reduce the frequency of episodes of Crohn’s disease, Crohn disease and ulcerative colitis, as well as the incidence of other gastrointestinal disorders and other medical conditions.”

Nexia has been on the market since early 2017, when it was discovered by the Mayo Clinic.

It has been studied in humans by scientists at the University of Florida and the University at Albany, and is expected to be approved for human use by the FDA in the fall.

The FDA said it expects Nexium to be available by the end of 2021.

The agency said the drug is not a new treatment and that Nexium is in the same class as other treatments.

It is still unclear when Nexium will be available for the general population.

The Drug Enforcement Administration and the Centers for Disease Control and Prevention also said Nexium may not be safe for use in children under age 6.

A recent review of Nexium by the drug’s manufacturer, Nexium Therapeutics, found that the drug can lead to side effects, including a loss of appetite, constipation and diarrhea.

The Food and Drugs Administration has been working on Nexium for about six years.

In the past two years, the agency has approved more than $1.8 billion in drugs for use by patients, according to the agency.